Sort   by:  
 Page size 
MetabolomicsMetabolome profiling by untargeted metabolomics and biomarker panel selection using machine-learning for patients in different stages of peripheral neuropathy induced by oxaliplatin

Background: Oxaliplatin-induced peripheral neuropathy (OIPN) poses a significant challenge for patients with colorectal tumor, often resulting in treatment interruption or discontinuation and subsequent treatment failure. Herein, a longitudinal untargeted metabolomic study to reveal the metabolom...

2025-08-14 | MTBLS12854 | MetaboLights
MetabolomicsAn explainable prognostic prediction panel for sepsis based on serum amino acid profiles

Sepsis is a life-threatening syndrome requiring aggressive management, and novel noninvasive biomarkers to enable risk stratification of sepsis with high confidence and to predict the sepsis-related outcomes are urgently needed. 

A mass spectrometry–based quantitative method was used t...

2026-05-24 | MTBLS14567 | MetaboLights
MetabolomicsUrine metabolomics phenotyping and urinary biomarker exploratory in mild cognitive impairment and Alzheimer's disease.

INTRODUCTION Alzheimer's disease is a prevalent disease with a heavy global burden and is suggested to be a metabolic disease in the brain in recent years. The metabolome is considered to be the most promising phenotype which reflects changes in genetic, transcript, and protein ...

2024-01-11 | MTBLS8662 | MetaboLights
MetabolomicsA metabolite-augmented FIB-4 machine learning panel achieves superior liver fibrosis staging in chronic liver disease

Accurate, non-invasive liver fibrosis detection is essential for chronic liver disease management, particularly with rising metabolic dysfunction-associated liver disease (MASLD) and chronic hepatitis B (CHB). While the Fibrosis-4 (FIB-4) index is widely used, its performance for advanced fibrosi...

2026-03-03 | MTBLS13946 | MetaboLights
MetabolomicsChronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study: Serum Lipidomics
The overall clinical study used a parallel-group, case-controlled study design in order to identify a biomarker or panel of biomarkers for the differentiation of subjects with mild to moderate COPD (GOLD stage I and II), asymptomatic current smokers, former smokers and never-smokers and to compare p...
2017-02-20 | MTBLS358 | MetaboLights
ProteomicsTowards a proteomic plasma biomarker panel for diagnosing vasculitis remission
Active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) requires intensive immunosuppressive therapy, but continued treatment after remission is achieved can cause serious harm. Reliable biomarkers to confirm remission are lacking, forcing clinicians to prolong cost-intens...
ORGANISM(S): Homo sapiens (Human) 
2026-06-05 | PXD079232 | Pride
Machine learning Vasculitis Multi-biomarker panel Plasma proteomics Anti-neutrophil cytoplasmic autoantibodies 
GenomicsA novel urinary microRNA biomarker panel for detecting gastric cancer
A novel urinary microRNA biomarker panel for detecting gastric cancer
PRJNA528633 | ENA
ProteomicsDevelopment a of novel targeted proteomic plasma biomarker panel for hypertrophic cardiomyopathy
Rationale There is a need for new and better biomarkers for hypertrophic cardiomyopathy (HCM) which correlate more closely with disease progression as determined by clinical imaging and biohumoral information. We have used a combination of heart tissue and plasma proteomics to identify potential bi...
ORGANISM(S): Homo sapiens (Human) 
2019-07-08 | PXD009859 | Pride
Human Lc-msms Hypertrophic cardiomyopathy Heart Plasma 
TranscriptomicsComparison between cell lines from 9 different cancer tissue (NCI-60) (Affymetrix U133 Plus 2.0)
Comparison between cell lines from 9 different cancer tissue of origin types (Breast, Central Nervous System, Colon, Leukemia, Melanoma, Non-Small Cell Lung, Ovarian, Prostate, Renal) from NCI-60 panel. Cell lines from 9 different cancer tissue of origin types
ORGANISM(S): Homo sapiens 
2011-09-28 | E-GEOD-32474 | biostudies-arrayexpress
ProteomicsA new multiplexed plasma biomarker panel developed using targeted proteomics and machine learning has diagnostic and prognostic potential in children with hypertrophic cardiomyopathy
Background Hypertrophic cardiomyopathy (HCM) is defined clinically by pathological left ventricular hypertrophy (LVH). We have previously developed a plasma proteomics biomarker panel that correlates with clinical markers of disease severity and sudden cardiac death (SCD) risk in adult patients with...
ORGANISM(S): Homo sapiens (Human) 
2024-07-03 | PXD045304 | Pride
Childhood-onset hcm proteomics 
Sort   by:  
 Page size